Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that UnitedHealth Group will provide preferred access to Praluent® (alirocumab) Injection through OptumRx and UnitedHealthcare for Commercial, …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively …
Analysts are weighing in on pharmaceutical giants Gilead Sciences, Inc. (NASDA:GILD), Regeneron Pharmaceuticals Inc (NASDAQ:REGN), and Abbott Laboratories (NYSE:ABT) with mixed ratings.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced a new post-hoc analysis of six Phase 3 clinical trials showing that approximately three quarters (74 percent) …
Stocks in the biotech sector are notoriously volatile pending financial earnings results and new drug trials. Analysts weigh in on CytRx Corporation (NASDAQ:CYTR) …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced financial results for the third quarter of 2015 and provided an update on development programs. Financial Highlights ($ in …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that Bayer HealthCare has received European approval for EYLEA® (aflibercept) Injection for the treatment of visual impairment due to …
Analysts weigh in on Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) as the company tries to defends itself against fraud allegations, and Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN), a leading science-driven biopharmaceutical company, today announced that it is investing an additional $350 million in its Limerick Industrial Operations …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced that the European Commission (EC) has granted marketing authorization for Praluent® (alirocumab) for the …
